Een dubbelblind, placebo-gecontroleerd fase 2 onderzoek naar de effecten van ARA 290 op neuropathische symptomen in patiënten met type 2 diabetes.
- Conditions
- type 2 diabetes mellitussmall fiber neuropathy (dunne vezel neuropathie)pain (pijn)eye exams (oogonderzoek)skin biopsy (huidbiopten)
- Registration Number
- NL-OMON21147
- Lead Sponsor
- eiden University Medical Center
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 50
Inclusion Criteria
1. Established diagnosis of diabetes mellitus type 2;
2. Screening HbA1c between 7.5 % and 10 % inclusive;
Exclusion Criteria
1. Clinically relevant abnormal history of physical and mental health other than conditions related to diabetes, as determined by medical history taking (as judged by the investigator);
2. Clinically relevant abnormal laboratory results, vital signs, or physical findings other than conditions related to diabetes (as judged by the investigator);
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
ARA 290 innate repair receptor activation mechanism diabetic small fiber neuropathy treatment
ARA 290 versus pregabalin duloxetine efficacy safety painful diabetic neuropathy comparison
Biomarkers ARA 290 response diabetic neuropathy corneal confocal microscopy IENFD prediction
ARA 290 safety profile adverse events non-erythropoietic EPO derivatives diabetic neuropathy trials
Non-erythropoietic EPO analogues innate repair receptor agonists diabetic neuropathy therapeutic development